✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Survodutide is a GLP-1 / glucagon dual agonist developed by Boehringer Ingelheim. Phase 2/3 in obesity and MASH.
- Phase 2 weight loss: -18.7% at 46 weeks at the 4.8 mg dose — deeper than mazdutide at longer timeframe.
- Striking hepatic-fibrosis effect. Phase 2 MASH data showed substantially higher fibrosis-resolution rates than GLP-1 monoagonism alone — the strongest published liver-effect in the incretin class.
- The glucagon arm is the differentiator from tirzepatide. Tirzepatide adds GIP; survodutide adds glucagon; the two are non-overlapping dual-agonist architectures.
- This guide covers mechanism, MASH-specific applicability, and where survodutide fits in obesity-pharma research.
Survodutide Peptide: GLP-1 / Glucagon Dual Agonist with MASH Activity
Survodutide (Boehringer Ingelheim BI 456906) is the GLP-1 / glucagon dual agonist that paired the deepest published hepatic-fibrosis effect in the incretin class with substantive obesity weight-loss data. The molecule’s strongest research case is in MASH / NASH protocols where the glucagon arm’s hepatic-lipid mechanism produces effects substantially larger than GLP-1 monoagonism. This guide covers the mechanism, the MASH-specific readout, and where survodutide fits in the broader research landscape.
What is survodutide
Survodutide is a synthetic peptide with dual GLP-1 and glucagon receptor agonism, acylated for albumin binding and supporting weekly subcutaneous dosing (half-life ~6 days). Boehringer Ingelheim developed the molecule with an explicit focus on the metabolic-hepatic axis — the glucagon arm’s hepatic effects are the strategic positioning rather than an incidental feature.
Mechanism
The dual-receptor architecture combines complementary mechanisms. GLP-1 agonism drives appetite suppression and slowed gastric emptying via the standard incretin pathway. Glucagon agonism is the differentiator — glucagon-receptor activation increases hepatic glucose output, direct hepatic energy expenditure, and (the strategically important effect) fatty-acid oxidation in hepatocytes. The hepatic-fatty-acid-oxidation mechanism is what underlies the MASH / fibrosis-resolution effect: chronic glucagon-arm activation in the hepatocyte produces sustained shift toward fat oxidation over fat storage, gradually reducing hepatic-triglyceride content and the inflammatory / fibrotic processes downstream.
The lack of a GIP arm (which tirzepatide and retatrutide both have) means survodutide produces purer GLP-1 + glucagon pharmacology without the enteroinsular-axis effects of GIP. For MASH research where the hepatic axis is the primary endpoint, this purity is a design advantage.
Research applications
The most-published research scenario is MASH / NASH. Phase 2 MASH-specific data showed substantially higher fibrosis-resolution rates than GLP-1 monoagonism alone — the strongest published liver-effect in the incretin class. The Phase 3 LIVERAGE program is evaluating survodutide in MASH with the hepatic-fibrosis endpoint as primary.
Other research scenarios: obesity weight-loss research (Phase 2 -18.7% at 46 wk is competitive within the dual-agonist class); diabetes research with hepatic-axis extension endpoints; mechanism research isolating GLP-1 + glucagon from GLP-1 + GIP (survodutide vs tirzepatide head-to-head).
Research dosing
Phase 2 / 3 protocols titrate from 0.3 mg weekly SC through 1.2 mg, 2.4 mg, and 3.6 mg to a 4.8 mg maintenance dose, each step lasting ~4 weeks. The slow titration manages GI tolerability; the glucagon-arm contribution to GI side effects appears modest relative to the GLP-1 arm’s dominant effect.
Side-effect profile
Class-level incretin signature: nausea, occasional vomiting, GI side effects most prominent in early titration. Glucagon-arm-specific considerations include modest blood-pressure effects and slight elevation in fasting glucose during titration (counterbalanced by GLP-1’s insulin-secretion-amplifying effect). The MASH-specific Phase 2 data showed favourable tolerability with substantial hepatic-endpoint improvement, suggesting the glucagon-arm hepatic effects are achieved without proportional adverse-event burden.
Comparator and stacking
Direct comparators: Survodutide vs Tirzepatide (the cross-architecture dual-agonist comparison — glucagon vs GIP as the second arm). For the broader cluster, see Best peptides for fat loss. Mazdutide is the other GLP-1 / glucagon dual agonist on the catalogue (different developer, different regulatory pathway).
Storage and reconstitution
Lyophilized vials at -20 °C long-term, 2-8 °C working stock. Reconstitute with bacteriostatic water. Reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Safety and regulatory status
Survodutide has no FDA / EMA / MHRA approval. Phase 3 LIVERAGE (MASH) and obesity programs are in progress. The research-grade compound is sold for in-vitro laboratory research and analytical reference use only. None of this constitutes medical advice.
FAQ
Why is the hepatic effect so strong with survodutide?
Because the glucagon receptor is heavily expressed on hepatocytes. Glucagon activation produces direct hepatic-fatty-acid oxidation, reducing hepatic-triglyceride content and the downstream inflammation / fibrosis. GIP (which tirzepatide has instead) acts predominantly on islet cells and adipose tissue, with much weaker hepatic effects.
How does survodutide compare to tirzepatide for weight loss?
Tirzepatide -22.5% at 72 wk; survodutide -18.7% at 46 wk. Tirzepatide is deeper at longer timeframe but the comparison is confounded by trial-duration difference. The substantial differentiator is MASH / hepatic effects where survodutide is substantially stronger. See: Survodutide vs Tirzepatide.
Will survodutide get FDA approval first as a MASH or obesity drug?
The MASH indication may be first because the hepatic-fibrosis effect is the strongest published differentiator and the LIVERAGE Phase 3 program is advancing. The obesity indication would be a parallel or subsequent submission.
What’s the typical research dose?
0.3 mg weekly SC titrating through 1.2, 2.4, 3.6 mg to a 4.8 mg maintenance dose, each step lasting approximately 4 weeks.
How does survodutide compare to mazdutide?
Both are GLP-1 / glucagon dual agonists with similar architecture. Different developers (Boehringer vs Innovent/Lilly), different regulatory pathways (FDA/EMA-led vs NMPA-led). Survodutide’s Phase 2 readout is deeper (-18.7% at 46 wk vs -11.1% at 24 wk) but the timeframe difference accounts for some of the gap.
Storage protocol?
Lyophilized at -20 °C long-term, 2-8 °C working; reconstituted at 2-8 °C use within 30 days; protect from light; never freeze-thaw.
Bottom line
Survodutide is the GLP-1 / glucagon dual agonist with the strongest published hepatic-fibrosis effect in the incretin class. The glucagon arm’s hepatic-fatty-acid oxidation mechanism produces substantial MASH / NASH effects beyond what GLP-1 monoagonism achieves. Weight-loss data is competitive within the dual-agonist class (-18.7% at 46 wk). For MASH-specific research, survodutide is the clearest molecular choice; for pure obesity research, the molecule is competitive with tirzepatide but trails on raw effect size. The Phase 3 LIVERAGE MASH program is the most-anticipated near-term readout.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.